Abstract

FORMULATION AND EVALUATION OF VILDAGLIPTIN IMMEDIATE RELEASE TABLET

Kauser Fatema*, Dr. S.R. Shahi, Dr. Zahid Zaheer and Shaikh Tauqeer

Abstract

Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus. The immediate release tablet of vildagliptin were prepared and evaluated to increase bioavailability. The tablets were prepared by direct compression method using simple excipients like microcrystalline cellulose, lactose anhydrous, disintegrant such as sodium starch glycolate and magnesium stearate were used in tablet formulation. The formulation were evaluated for various physical parameters, dissolution study and drug release profile. From all formulations the formulation F08 showed 102 % drug release within 45 minutes, which was highest drug release than other batches. The optimized immediate release tablet of formulation F08 showed no change in physical appearance, drug content or in dissolution pattern storage at 40± 20 C / 75 ± 5 % for 90 days. Finally it was concluded that F08 shows highest drug release, which was close similar to marketed product.

Keywords: Immediate release tablet, Vildagliptin, Dissolution, Direct Compression.